Angelman Syndrome Foundation's News Room is an aggregation of several sources. We will post exciting announcements pertaining to ASF in addition to news about Angelman syndrome from within our community and from external media sources. See a story you think we should share? Send an email to email@example.com with the information. Thank you!
Research from the lab of Dr. Mark Zylka, a leading AS researcher and associate professor of cell biology and physiology at the University of North Carolina-Chapel Hill, has made a few exciting discoveries related to Angelman syndrome.
My trek to the top of Mt. Kilimanjaro is a small tribute to my son Madden and everyone with Angelman syndrome.
Fundraising for the Angelman Syndrome Foundation (ASF) National Walk continues until the $1.25 million fundraising goal is achieved. More than $1 million has been raised so far (in preliminary totals) in support of Angelman syndrome research and families--help us reach the goal!
Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome . . .
Ovid Therapeutics and Lundbeck A/S pharmaceuticals have entered into a worldwide licensing agreement for Gaboxadol, a drug that Ovid plans to use in separate upcoming clinical trials to treat Angelman syndrome and Fragile X syndrome.